RBTT-07. A PHASE 2 TRIAL OF PEMBROLIZUMAB AND BEVACIZUMAB IN MELANOMA BRAIN MET PATIENTS

BACKGROUND: Pembro monotherapy (NCT02085070) produces responses in 26% of (mel) BrM pts. VEGF inhibitors (VEGFi) enhance anti-PD-1 activity in preclinicals. Therefore, we initiated a phase 2 study (NCT02681549) of pembro plus bev in BrM pts. METHODS: Eligibility includes advanced mel, > 1 asympto...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Kluger, Harriet M, Forsyth, Peter, Khushalani, Nikhil, Eroglu, Zeynep, Sznol, Mario, Tran, Thuy, Jilaveanu, Lucia, Cohen, Justine V, Hegde, Upendra, Wei, Wei, Mahajan, Amit, Goldberg, Sarah B, Chiang, Veronica, Weiss, Sarah A
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Randomized Brain Tumor Trials in Development
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847787/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.919
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados